Avacta Group Plc

Avacta Group Plc AVCT

Dividend Summary



There have not been any declared dividends recently.

Latest Dividends
Summary Previous dividend Next dividend
Status
Type
Per share
Declaration date
Ex-div date
Pay date

Enter the number of Avacta Group Plc shares you hold and we'll calculate your dividend payments:

Previous Payment
Next Payment
Forecast Accuracy
We have not made any dividend predictions for Avacta Group Plc
Dividend Yield Today
0.0%
The dividend yield is calculated by dividing the annual dividend payment by the prevailing share price
The table below shows the full dividend history for Avacta Group Plc
Status Type Decl. date Ex-div date Pay date Decl. Currency Forecast amount Decl. amount Accuracy
There are no Avacta Group Plc dividends.
Year Amount Change
2006 0.0p
2007 0.0p
0%
2008 0.0p
0%
2009 0.0p
0%
2010 0.0p
0%
2011 0.0p
0%
2012 0.0p
0%
2013 0.0p
0%
2014 0.0p
0%
2015 0.0p
0%
2016 0.0p
0%
2017 0.0p
0%
2018 0.0p
0%
2019 0.0p
0%
2020 0.0p
0%
2021 0.0p
0%
2022 Sign Up Required

Avacta Group Plc Optimized Dividend Chart

The chart below shows the optimized dividends for this security over a rolling 12-month period.
Dividend Yield Today
0.0%
Optimized Yield
Sign Up Required
52 Week High
0.0% on 18 November 2021
52 Week Low
0.0% on 18 November 2021
Next Ex-Div-Date Countdown
Sign Up Required

About Avacta Group Plc

Avacta Group plc (Avacta) is a United Kingdom-based clinical stage oncology drug company. The Company is focused on developing cancer immunotherapies and diagnostics based on its Affimer and prelCISION platforms. It has two divisions: Therapeutics and Diagnostics. Avacta’s therapeutics division develops cancer immunotherapies combining its platforms: Affimer biotherapeutics and prelCISION tumor targeted chemotherapy. The Affimer platform is a class of biotherapeutic based on a naturally occurring human protein. Avacta's prelCISION targeted chemotherapy platform releases active chemotherapy in the tumor, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these anti-cancer treatments. Avacta’s diagnostics division utilizes its Affimer platform to develop diagnostics and works with partners world-wide to develop Affimer reagents with the objective of establishing royalty-bearing license deals.

Sector
Pharmaceuticals & Biotechnology
Country
United Kingdom
Share Price
£1.02 (yesterday's closing price)
Shares in Issue
253 million
Market Cap
£258mn
CADI
The Consecutive Annual Dividend Increases - the number of years this company has been increasing its dividends
0
Market Indices
none
No articles found